Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Radiopharmaceuticals are becoming an essential tool in the fight against cancer, and the field has been diversified with the investigation of f-block elements over the past decade. Here we discuss the highlights in 2023 research leading the charge in utilizing f-block elements in innovative ways, changing how we treat these diseases.
Targeted covalent inhibitors (TCIs) can react irreversibly with lysine in kinases and other proteins. Small molecule TCIs can have both broad or specific lysine targeting whereas peptide- and protein-based TCIs were shown to provide high target specificity for lysines in shallow protein surfaces.
Three unprecedented selective bioconjugation methods for serine, methionine and lysine have been realized. Specifically, chemoselectivity for serine, site-selectivity for methionine and site-specificity for lysine were achieved.
